| Stuart A. Aaronson, M.D. | |
|---|---|
| Born | February 28, 1942 Mount Clemens, Michigan |
| Alma mater | UC Berkeley, UC SF |
| Occupation | biologist |
| Employer | Mount Sinai Medical Center |
| Known for | Cancer research |
| Title | Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Chairman of Oncological Sciences |
Stuart A. Aaronson, M.D. , is an American author and internationally recognized cancer biologist.[1][2] He has authored more than 500 publications and holds over 50 patents, and is currently the Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Chairman of Oncological Sciences at Mount Sinai Medical Center in New York City.[3]
Contents |
Aaronson graduated summa cum laude from the University of California, Berkeley, in 1962, with a degree in chemistry. He earned his M.D. from the University of California, San Francisco Medical Center in 1966, and completed a fellowship at the University of Cambridge in England and an internship in medicine at Moffitt Hosptial in San Francisco.[3]
In 1967, Aaronson joined the National Institutes of Health as a Senior Staff Fellow. He headed the Molecular Biology Section of the Viral Carcinogenesis Branch from 1970 until 1977, after which he became Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute, until 1993, when he was named Chairman of Oncological Sciences at Mount Sinai Medical Center.
Aaronson's early research established the transformation-competent but replication-defective nature of mammalian sarcoma viruses and molecularly cloned many of their oncogenes.[3][4] His investigations of the v-sis oncogene established the first normal function of an oncogene and its role in growth factor signaling.[1][2] His discovery of erbB2 as a v-erbB-related gene amplified in a human breast carcinoma and the demonstration of its transforming properties paved the way for targeted therapies directed against its product,[4] and his successful isolation of KGF (FGF7), a growth factor present in the epithelialization-phase of wound healing, led to Amgen's successful phase III clinical trial and FDA approval of KGF for treatment of mucositis.[5][6] Current research includes investigations into the mechanisms by which tumor suppressor genes induce permanent growth arrest/senescence, the signaling pathways involved, and investigations of the autocrine and paracrine acting growth factors PDGF, KGF, HGF, and Wnt ligands.[3]
Partial list:
| Patent Number | Title |
|---|---|
| 6479255[7] | Polynucleotides encoding human FRP and fragments thereof |
| 6225088[8] | DNA encoding plasminogen-like growth factor (PLGF) and related embodiments |
| 6228600[9] | Immunoassays for the alpha platelet-derived growth factor receptor |
| 6403769[10] | Fusion proteins that include antibody and nonantibody portions |
| 6566098[11] | DNA encoding truncated hepatocyte growth factor variants |
| 6639060[12] | erbB-3 nucleic acids |
| 6653084[13] | Anti-erbB-2 antibodies to human receptor related to but distinct from EGF receptor |
| 6660488[14] | Antibodies for the alpha platelet-derived growth factor receptor |
| 6709842[15] | DNA encoding a growth factor specific for epithelial cells |
| 6833132[16] | Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity |
Partial list: